How it works, simply
It activates GLP-1 and GIP receptors.
What the evidence tells us
Roche reported Phase 2 topline results in type 2 diabetes with overweight or obesity. This disclosure is not regulatory approval or a substitute for the full study report.
Sponsor-reported results need to be read alongside the full trial design, outcomes and adverse events.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This guide does not establish a safe dose, interaction profile or long-term safety for self-use. Effects reported for one route or formulation may not apply to another.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates GLP-1 and GIP receptors.
Sponsor or developer: Roche
Studied or labeled topics: Obesity, Metabolic disease
2026-09-22: Sponsor-reported Phase 2 diabetes results; ENITH-1 and ENITH-2 Phase 3 weight-management studies ongoing.
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- Roche: CT-388 Phase 2 results and ENITH program ↗ · Sponsor · 2026-09-22
Readability updated October 10, 2026. Evidence review: September 23, 2026 (listed facts only). A wording update is not a new clinical review.